Any feedback?
Literature summary for 2.6.1.2 extracted from
- Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3-4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a (2008), Scand. J. Gastroenterol., 43, 1122-1127.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | patients with hepatitis C treated with NS3-4A protease inhibitor telaprevir and/or peginterferon alpha-2a. Patients receiving telaprevir alone show a decrease in mean neopterin and alanine aminotransferase levels. Patients receiving peginterferon alpha-2a plus telaprevir or peginterferon alpha-2a plus placebo show an ioncrease in neopterin levels and decrease in alanine aminotransferase level, suggesting that treatment of chronic hepatitis C patients with an NS3-4A protease inhibitor ameliorates inflammation. Interferon-mediated immunomodulatory effects remain intact when interferon is combined with telaprevir | Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
hepatitis C patients | - |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
